Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case-Control Study

Medicina (Kaunas). 2025 Nov 20;61(11):2065. doi: 10.3390/medicina61112065.

Abstract

Background and Objectives: Multiple myeloma (MM) remains an incurable plasma cell malignancy with heterogeneous clinical outcomes. Although current prognostic systems integrate biochemical and cytogenetic parameters, they do not fully capture disease complexity. Adipocytes within the bone marrow microenvironment secrete adipokines that regulate inflammation, metabolism, and immune interactions and may influence disease progression. This study aimed to assess circulating adipokines and related microenvironmental mediators as potential biomarkers of disease activity and treatment response in MM. Materials and Methods: In this case-control, cross-sectional study, the serum levels of eight adipokine-related molecules-adiponectin, leptin, resistin, chemerin, adipsin, thrombospondin-1 (TSP-1), paraoxonase-1 (PON-1), and myeloperoxidase (MPO)-were measured in 40 MM patients and 38 age- and sex-matched healthy controls. Enzyme-linked immunosorbent assays (ELISA) and bead-based multiplex immunoassays were used. Associations with prognostic markers (serum β2-microglobulin (sB2M), LDH, albumin, hemoglobin, renal function) and treatment response were analyzed using correlation and non-parametric statistical methods. Results: Compared to the controls, MM patients exhibited significantly higher circulating levels of adiponectin, resistin, chemerin, adipsin, TSP-1, and MPO, while leptin was decreased. Among clinical correlations, chemerin and PON-1 correlated positively with sB2M, TSP-1 correlated with LDH, and MPO correlated with M-protein and albumin. Resistin was lower in patients with renal impairment and an advanced disease stage. Adiponectin and TSP-1 were significantly lower in progressive disease compared to complete remission, suggesting their potential association with treatment response. Conclusions: This study demonstrates that multiple adipokines are dysregulated in MM and exhibit distinct associations with disease burden, renal function, and therapeutic response. Novel associations identified for TSP-1, PON-1, and adipsin highlight previously unrecognized microenvironmental pathways in MM biology. Adipokine profiling may complement established prognostic markers and provide new insights into the tumour microenvironment in MM.

Keywords: adiponectin; adipsin; chemerin; leptin; multiple myeloma; myeloperoxidase; paraoxonase-1; prognostication; resistin; thrombospondin-1.

MeSH terms

  • Adipokines* / analysis
  • Adipokines* / blood
  • Adiponectin / analysis
  • Adiponectin / blood
  • Aged
  • Aryldialkylphosphatase / analysis
  • Aryldialkylphosphatase / blood
  • Biomarkers / analysis
  • Biomarkers / blood
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / blood
  • Case-Control Studies
  • Chemokines / analysis
  • Chemokines / blood
  • Cross-Sectional Studies
  • Female
  • Humans
  • Leptin / analysis
  • Leptin / blood
  • Male
  • Middle Aged
  • Multiple Myeloma* / blood
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / physiopathology
  • Peroxidase / analysis
  • Peroxidase / blood
  • Prognosis
  • Resistin / analysis
  • Resistin / blood
  • Thrombospondin 1 / analysis
  • Thrombospondin 1 / blood
  • beta 2-Microglobulin / analysis
  • beta 2-Microglobulin / blood

Substances

  • Adipokines
  • Biomarkers
  • Leptin
  • Thrombospondin 1
  • Adiponectin
  • Resistin
  • Biomarkers, Tumor
  • Peroxidase
  • Chemokines
  • Aryldialkylphosphatase
  • RARRES2 protein, human
  • beta 2-Microglobulin